Square Pharmaceuticals (DHA:SQURPHARMA) Net Income From Continuing Operations : BDT19,600 Mil (TTM As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Square Pharmaceuticals Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Square Pharmaceuticals's net income from continuing operations for the three months ended in Dec. 2023 was BDT6,177 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was BDT19,600 Mil.

Square Pharmaceuticals Net Income From Continuing Operations Historical Data

The historical data trend for Square Pharmaceuticals's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Square Pharmaceuticals Net Income From Continuing Operations Chart

Square Pharmaceuticals Annual Data

Trend

Mar14

Mar15

Mar16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Net Income From Continuing Operations

Get a 7-Day Free Trial

11,720.70

12,767.40

15,947.45

18,157.18

18,980.14

Square Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Income From Continuing Operations	Get a 7-Day Free Trial															5,564.97	4,282.87	4,070.82	5,068.76	6,177.20

Square Pharmaceuticals Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT19,600 Mil.

Square Pharmaceuticals (DHA:SQURPHARMA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Square Pharmaceuticals PLC (DHA:SQURPHARMA) » Definitions » Net Income From Continuing Operations

Traded in Other Exchanges

N/A

Address

Square Centre, 48, Mohakhali Commercial Area, Dhaka, BGD, 1212

Website

http://www.squarepharma.com.bd

Square Pharmaceuticals PLC is a Bangladesh-based pharmaceutical company engaged in the manufacturing and marketing of generic pharmaceuticals products, Basic chemical products, and animal health products. It manufactures drugs like paracetamol, clotrimazole, antiallergic, Nitroglycerin, xylometazoline HCl, erythromycin, and various other drugs. The company operates in Bangladesh and sells its products locally and internationally. The company operates in one segment, which is the business of developing, manufacturing, and marketing drugs.

Square Pharmaceuticals (DHA:SQURPHARMA) Headlines

No Headlines